Jacobson Pharma Corporation Limited (HKG:2633)
0.9350
-0.0100 (-1.06%)
Oct 30, 2026, 3:00 PM HKT
HKG:2633 Revenue
In the fiscal year ending March 31, 2026, Jacobson Pharma Corporation had annual revenue of 1.57B HKD, down -0.47%. Jacobson Pharma Corporation had revenue of 802.91M in the half year ending March 31, 2026. That makes Jacobson Pharma Corporation the 17,491st largest company in the world by revenue and 1,009th in Hong Kong.
Revenue
1.57B
Revenue Growth
-0.47%
P/S Ratio
1.19
Revenue / Employee
887.71K
Employees
1,768
Market Cap
1.87B
Revenue by Geography
- Hong Kong 1.51B 96.5%
- Macau 31.59M 2.0%
- Mainland China 23.34M 1.5%
- Others 202.00K 0.0%
Fiscal year ended Mar 31, 2026 See the full HKG:2633 breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 1.57B | -7.43M | -0.47% |
| Mar 31, 2025 | 1.58B | 109.10M | 7.43% |
| Mar 31, 2024 | 1.47B | 200.20M | 15.79% |
| Mar 31, 2023 | 1.27B | -327.95M | -20.55% |
| Mar 31, 2022 | 1.60B | 149.63M | 10.35% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| CPBIO Holding Company | 3.32B |
| Edding Genor Group Holdings | 2.57B |
| Essex Bio-Technology | 1.72B |
| Dawnrays Pharmaceutical (Holdings) | 1.32B |
| Golden Throat Holdings Group Company | 1.04B |
| Jilin Province Huinan Changlong Bio-pharmacy Company | 1.04B |
| JBM (Healthcare) | 834.63M |
| Hua Medicine (Shanghai) | 755.49M |